ProQR Therapeutics N.V. reports developments as a clinical-stage biopharmaceutical company built around its proprietary Axiomer™ RNA editing platform. The technology uses ADAR-mediated RNA editing to make single-nucleotide changes in RNA, with pipeline updates centered on AX-0810 and additional programs across rare and prevalent diseases with unmet need.
Recurring company news includes scientific conference presentations, investor and analyst events, clinical-program updates, development-candidate selections, AI-enabled discovery initiatives, and collaborations such as Ginkgo Bioworks and Eli Lilly. ProQR also reports annual operating and financial results, annual general meeting materials, board composition changes, and other governance matters tied to its Nasdaq-listed public-company profile.
Summary not available.
ProQR Therapeutics NV (Nasdaq: PRQR) announced its participation in several upcoming investor conferences to discuss its innovative RNA therapies using the Axiomer® RNA editing technology platform. Key events include:
- Van Lanschot Kempen Life Sciences Conference – April 26, Amsterdam (1x1 meetings only)
- JMP Securities Life Sciences Conference – May 16, New York (Fireside chat at 12:30 PM EDT)
- Stifel 2023 Tailoring Genes: Genetic Medicines Day – May 30, Virtual (Fireside chat, time TBC)
Details on presentations and webcasts will be available on the company’s website. ProQR is focused on advancing RNA therapies that address both rare and common diseases, utilizing its unique Axiomer® technology for precise RNA editing.
ProQR Therapeutics NV (Nasdaq: PRQR) announced its Annual General Meeting (AGM) of Shareholders scheduled for May 17, 2023, at 16:00 CET, in Amsterdam. Key updates include the nomination of Begoña Carreño and Theresa Heggie to the Supervisory Board, along with Bart Filius for re-election. Notably, Antoine Papiernik will rotate off the Board. Carreño brings over 20 years of experience in pharmaceutical development and strategy from Novartis, while Heggie has a strong background in commercial operations at Alnylam Pharmaceuticals. ProQR focuses on transformative RNA therapies utilizing its proprietary Axiomer® RNA editing technology, aiming to provide innovative treatment options for diseases with unmet needs.
ProQR Therapeutics NV (Nasdaq: PRQR) announced initial pipeline programs focused on liver diseases, introducing AX-0810 targeting NTCP for cholestatic diseases and AX-1412 targeting B4GALT1 for cardiovascular disease. Clinical trials are expected to start in late 2024 or early 2025. The company reported year-end 2022 financials, with a cash reserve of €94.8 million, extended cash runway into mid-2026, and a net loss of €64.9 million. Notable preclinical activity was reported, with up to 50% RNA editing observed in both rodent and non-human primate models, showcasing the Axiomer platform's potential.
ProQR Therapeutics (Nasdaq: PRQR) recently defended its key patent for the Axiomer® RNA editing platform against two oppositions filed in February 2021. The European Patent Office ruled in favor of ProQR after a public hearing held on March 7 and 8, 2023. This patent is crucial for ProQR’s intellectual property, which includes 22 patents across 10 families. The company emphasizes that its robust patent estate positions it as a leader in the field of RNA editing technology. ProQR aims to develop transformative therapies for diseases using its innovations in RNA editing.
ProQR Therapeutics N.V. (Nasdaq: PRQR) announced key presentations at upcoming conferences to showcase its Axiomer® RNA editing platform. Events include the Oligonucleotide and Precision Therapeutics (OPT) Congress on March 14, 2023, where CSO Gerard Platenburg will discuss therapeutic potentials of Editing Oligonucleotides (EONs). Additionally, at the RNA Leaders Europe Congress on March 16, 2023, CEO Daniel A. de Boer will explore the transformative capabilities of Axiomer. The RNA Editing Gordon Research Conference on March 23, 2023, will feature Platenburg's insights into addressing liver disorders with Axiomer. This innovative platform aims to revolutionize RNA therapies for various unmet medical needs.
ProQR Therapeutics N.V. (Nasdaq: PRQR) will host a virtual R&D event on March 29, 2023, from 10:00 am to 12:30 pm EDT. The event will feature the Company’s Axiomer® RNA-editing technology and outline initial pipeline targets for development. Key speakers include CEO Daniel A. de Boer and Chief Scientific Officer Gerard Platenburg. The Company will also release its full year 2022 operating and financial results on the same date. Registration for the event is available on ProQR's website, and an archived webcast will be accessible for 30 days post-event. This initiative underscores ProQR's commitment to advancing RNA therapies aimed at treating diverse diseases.
ProQR Therapeutics N.V. (Nasdaq: PRQR) has announced an investor conference call and webcast on December 22, 2022, at 8:15am EST to discuss its Axiomer RNA editing technology, following an expanded partnership with Eli Lilly. The Axiomer platform utilizes the body's own ADAR machinery to edit RNA, potentially leading to new treatments for various diseases. The call will be accessible live and archived for 30 days. ProQR aims to develop transformative RNA therapies that address significant unmet medical needs.
ProQR Therapeutics and Eli Lilly expand their collaboration to develop genetic medicines using Axiomer technology. The updated agreement, initially forged in September 2021, aims to enhance RNA editing for liver and nervous system disorders. ProQR will receive $75 million in upfront payment and equity, with potential total earnings of $3.75 billion in milestones and royalties. The collaboration signifies a strong commitment to addressing high unmet medical needs.
Eli Lilly and ProQR Therapeutics announced an expanded collaboration on December 22, 2022, focusing on genetic medicines utilizing ProQR's Axiomer RNA editing technology. The partnership, originally established in September 2021, will now target additional disorders affecting the central and peripheral nervous systems. ProQR will receive $75 million upfront and an option for an additional $50 million. The total potential value of the collaboration is approximately $3.75 billion in milestones and royalties. This collaboration aims to develop innovative treatments for diseases with significant unmet needs.